6.85
0.18 (2.7%)
0.18 (2.7%)
Upgrade to Real-Time
Afterhours (Closed)
Low
3.12
High
24.34
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Bio Path Holdings Inc | BPTH | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.18 | 2.7% | 6.85 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 6.76 | 6.30 | 7.00 | 6.85 | 6.67 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 6.65 | 7.10 | 0.45 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,668 | 279,261 | $ 6.74 | $ 1,882,756 | 205,645 | 3.12 - 24.34 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:38:15 | 50 | $ 6.88 | USD |
Bio Path Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 47.68M | 6.96M | 6.93M | $ - | $ - | -2.82 | -2.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 153.00k | - |
Bio Path News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BPTH Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.88 | 7.1999 | 5.70 | 6.34 | 236,636 | 0.97 | 16.5% |
| 1 Month | 5.05 | 7.1999 | 5.00 | 6.00 | 201,083 | 1.80 | 35.64% |
| 3 Months | 7.17 | 10.17 | 5.00 | 7.14 | 613,946 | -0.32 | -4.46% |
| 6 Months | 4.50 | 24.34 | 3.47 | 9.65 | 1,331,937 | 2.35 | 52.22% |
| 1 Year | 5.26 | 24.34 | 3.12 | 8.23 | 943,453 | 1.59 | 30.23% |
| 3 Years | 33.20 | 73.52 | 1.60 | 12.43 | 743,810 | -26.35 | -79.37% |
| 5 Years | 478.00 | 504.00 | 1.60 | 34.25 | 588,598 | -471.15 | -98.57% |
Bio Path Description
| Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003. |
